Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant acinetobacter baumannii

Chemotherapy

Volumn 59, Issue 3, 2014, Pages 225-231

  Garnacho Montero, José ^a,b   Amaya Villar, Rosario ^a,b   Gutiérrez Pizarraya, Antonio ^b,c   Espejo Gutiérrez De Tena, Esther ^a   Artero González, M Luisa ^d   Corcia Palomo, Yael ^a   Bautista Paloma, Javier ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c Infectious Diseases Service   (Spain)

^d Fundacion Publica Andaluza para la Gestion de la Investigacion en Salud de Sevilla   (Spain)

Author keywords

Acinetobacter baumannii; Colistin; Vancomycin

Indexed keywords

CARBAPENEM; COLISTIN; VANCOMYCIN; AMINOGLYCOSIDE; BILIRUBIN; CREATININE; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; VENTILATOR ASSOCIATED PNEUMONIA; ACUTE KIDNEY FAILURE; BACTERIAL CLEARANCE; BACTERIAL PNEUMONIA; BILIRUBIN BLOOD LEVEL; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DRUG TOLERABILITY; DRUG WITHDRAWAL; INTENSIVE CARE UNIT; LENGTH OF STAY; MINIMUM INHIBITORY CONCENTRATION; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT DURATION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84890484205     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000356004     Document Type: Article

References (34)

1. Llaca-Díaz JM, Mendoza-Olazarán S, Cama-cho-Ortiz A, Flores S, Garza-González E: One-year surveillance of ESKAPE pathogens in an intensive care unit of Monterrey, Mexico. Chemotherapy 2012; 58:475-481.
2. Garnacho-Montero J, Amaya-Villar R: Multi-resistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010; 23:332-339.
3. Vila J, Pachón J: Therapeutic options for Aci-netobacter baumannii infections. Expert Opin Pharmacother 2008; 9:587-599. (Pubitemid 351425386)
4. Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, et al: Efficacy of colistin versus beta-lactams, aminoglycosides, and ri-fampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acineto-bacter baumannii. Antimicrob Agents Che-mother 2002; 46:1946-1952. (Pubitemid 34535219)
5. Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, Jimé-nez-Mejias ME, García-Curiel A, et al: Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imi-penem-resistant Acinetobacter baumannii. Antimicrob Agents Chemot her 2010; 54: 1165-1172.
6. Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA, et al: Intravenous co-listin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008-1011. (Pubitemid 29203530)
7. Oliveira MS, Prado GVB, Costa SF, Grin-baum RS, Levin AS: Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008; 61:1369-1375. (Pubitemid 351753609)
8. Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, et al: Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010; 65: 1019-1027.
9. Gordon NC, Png K, Wareham DW: Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54:5316-5322.
10. Wareham DW, Gordon NC, Hornsey M: In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Che-mother 2011; 66:1047-1051.
11. Hornsey M, Wareham DW: In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother 2011; 55:3534-3537.
12. Calandra T, Cohen J: The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005; 33:1538-1548. (Pubitemid 40980610)
13. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829. (Pubitemid 15250137)
14. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655.
15. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31.
16. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al: Population phar-macokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55:3284-3294.
17. Tan TY, Ng LSY, Tan E, Huang G: In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter bau-mannii clinical isolates. J Antimicrob Che-mother 2007; 60:421-423. (Pubitemid 47243898)
18. Sopirala MM, Mangino JE, Gebreyes WA, Bill-er B, Bannerman T, Balada-Llasat J-M, et al: Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimi-crob Agents Chemother 2010; 54:4678-4683.
19. Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW: In vitro activity of colistin or sul-bactam in combination with fosfomycin or imipenem against clinical isolates of carbape-nem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health 2011; 42:890-900.
20. O'Hara JA, Ambe LA, Casella LG, Townsend BM, Pelletier MR, Ernst RK, et al: Activities of vancomycin-containing regimens against co-listin-resistant Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother 2013; 57:2103-2108.
21. Vidaillac C, Benichou L, Duval RE: In vitro synergy of colistin combinations against colis-tin-resistant Acinetobacter baumannii, Pseu-domonas aeruginosa, and Klebsiella pneumoni-ae isolates. Antimicrob Agents Chemother 2012; 56:4856-4861.
22. Hornsey M, Longshaw C, Phee L, Wareham DW: In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens. Antimicrob Agents Che-mother 2012; 56:3080-3085.
23. Vaara M, Siikanen O, Apajalahti J, Fox J, Fri-modt-Møller N, He H, et al: A novel polymyx-in derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob Agents Che-mother 2010; 54:3341-3346.
24. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC Jr, Mylonakis E: Galleria mel-lonella as a model system to study Acineto-bacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother 2009; 53: 2605-2609.
25. Hornsey M, Phee L, Longshaw C, Wareham DW: In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Int J Antimicrob Agents 2013; 41:285-287.
26. Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC: What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012; 54:670-680.
27. Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, et al: Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: a matched case-control study. Crit Care Med 2008; 36:807-811.
28. Michalopoulos AS, Tsiodras S, Rellos K, Men-tzelopoulos S, Falagas ME: Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11:115-121. (Pubitemid 40259694)
29. Deryke CA, Crawford AJ, Uddin N, Wallace MR: Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimi-crob Agents Chemother 2010; 54:4503-4505.
30. Doshi NM, Mount KL, Murphy CV: Nephro-toxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 2011; 31:1257-1264.
31. Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB: Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012; 56:2392-2396.
32. Falagas ME, Fragoulis KN, Kasiakou SK, Ser-maidis GJ, Michalopoulos A: Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005; 26: 504-507. (Pubitemid 41635502)
33. Plachouras D, Karvanen M, Friberg LE, Papa-domichelakis E, Antoniadou A, Tsangaris I, et al: Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 2009; 53:3430-3436.
34. Harigaya Y, Bulitta JB, Forrest A, Sakoulas G, Lesse AJ, Mylotte JM, et al: Pharmacodynam-ics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resis-tant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimi-crob Agents Chemother 2009; 53: 3894-3901.